In the only two clinical trials that have been conducted on n-3 LCPUFA therapy in TB patients, a positive effect was found on sputum smear conversion, body weight gain, inflammation resolution, and CD4+ T cell count (88, 89). Here, CD4 is linked to tuberculosis.